KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to 35.89%.

  • Esperion Therapeutics' EBITDA Margin rose 212900.0% to 35.89% in Q3 2025 from the same period last year, while for Sep 2025 it was 34.84%, marking a year-over-year decrease of 54700.0%. This contributed to the annual value of 15.57% for FY2024, which is 1643000.0% up from last year.
  • As of Q3 2025, Esperion Therapeutics' EBITDA Margin stood at 35.89%, which was up 212900.0% from 15.45% recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' EBITDA Margin registered a high of 44.3% during Q1 2024, and its lowest value of 1139.82% during Q1 2021.
  • Its 5-year average for EBITDA Margin is 230.25%, with a median of 174.71% in 2023.
  • As far as peak fluctuations go, Esperion Therapeutics' EBITDA Margin skyrocketed by 31136000bps in 2021, and later tumbled by -2448000bps in 2022.
  • Over the past 5 years, Esperion Therapeutics' EBITDA Margin (Quarter) stood at 423.02% in 2021, then skyrocketed by 30bps to 294.38% in 2022, then skyrocketed by 41bps to 174.71% in 2023, then skyrocketed by 82bps to 30.85% in 2024, then dropped by -16bps to 35.89% in 2025.
  • Its EBITDA Margin was 35.89% in Q3 2025, compared to 15.45% in Q2 2025 and 62.24% in Q1 2025.